Experts urge clinicians to focus on stroke prevention benefits when counseling patients about carotid revascularization.

Mavacamten (Camzyos) is now approved by the US Food and Drug Administration for use not only in adults, but also in pediatric patients with obstructive hypertrophic cardiomyopathy (HCM) who weigh at ...

ESC 2026 captured the biggest share of our top slots, but readers were most keen to learn about the first FDA approval of ...

Identifying regions with expertise can improve how patients access those best at managing the disease, Richard Soucier says.

A retrospective analysis shows that when CMR and FDG PET/CT findings are concordant, patients are more vulnerable to events.

The findings align with the PROLONG registry and bolster evidence for limiting the duration of antithrombotic therapy.